Media Contact
Have media inquiries? Contact us between 9 a.m. and 5 p.m. ET, Monday through Friday.
Vice President Stakeholder Engagement
More COVID-19 Questions and Answers
The ways we need to live our lives in the midst of this global COVID-19 pandemic is changing daily as federal and provincial governments ask us to hunker down, schools and businesses are shutting down or moving to virtual settings. We continue to hear every day from Canadians affected by blood cancers about how they should navigate their treatment and care in this confusing time. You asked and we’re respon...
The Coronavirus (Covid-19) and You...
The Leukemia & Lymphoma Society of Canada is closely monitoring the developments on the coronavirus disease (COVID-19) outbreak and how it might impact Canadians affected by blood cancers. Some people in treatment may be worried about the supply of therapeutic drugs (such as Imbruvica or Ibrutinib) produced in China. Its manufacturer Pharmacyclics is closely monitoring the situation and at this time, does not ...
Save more lives this #GivingTuesday
A blood cancer diagnosis can feel overwhelming.
Thanks to your support, one thing patients and their loved ones never have to worry about is the behind-the-scenes work of researchers across the country.
Whether scientists are exploring the underlying cause of blood cancers or new treatment options, we’re making progress on so many fronts.
And it’s all because of you.
CAR T-cell therapy now available in Quebec
Children and young adults with acute lymphoblastic leukemia (ALL) and adults with diffuse large B-cell lymphoma (BCGLD) who have not responded to standard treatments will be able to take advantage of CAR T-Cell Therapy. Two facilities offer this treatment: the Sainte-Justine University Hospital Center (CHU Sainte-Justine), for children, and the Maisonneuve-Rosemont Hospital (HMR) of the CIUSSS Eas...